No Data
Express News | Sunlight Nonoh: Director and Audit and Risk Committee member Zhang Ying resigns.
Express News | The CAR-T therapy developed through collaboration between Sunshine Theranostics and ArtMed Shenzhou has been approved to enter the clinical trial phase for systemic lupus erythematosus.
Express News | Sunshine Novo: The collaborative research and development project ZM001 injection received a clinical trial approval letter.
Sun-Nor(688621): Q3 revenue exceeds expectations, continuous increase in research and development investment.
Event: On October 28, the company released the third quarter report of 2024. In the first three quarters of 2024, the revenue was 0.917 billion yuan, a year-on-year increase of 32.47%, and the net income attributable to the parent company was 0.208 billion yuan, a year-on-year increase of 2.
Sunshine Nuohe (688621): Clinical high-speed release, bullish on sustainability.
Investment Highlights Performance: Income continues to grow at a high rate, with quarterly fluctuations in profit growth in 2024Q1-3 achieving revenue of 0.917 billion yuan, yoy +32.47%; achieving net income attributable to equity holders of 0.208 billion yuan, yoy +21.40.
Sunshine Novo: Third Quarter Report 2024
No Data
No Data